Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium
Tweet this page

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

  • The TNT trial comparing docetaxel to carboplatin
  • The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
  • Pembrolizumab in a phase Ib study

Advertisement

Advertisement



Advertisement